JP2010518082A5 - - Google Patents

Download PDF

Info

Publication number
JP2010518082A5
JP2010518082A5 JP2009549102A JP2009549102A JP2010518082A5 JP 2010518082 A5 JP2010518082 A5 JP 2010518082A5 JP 2009549102 A JP2009549102 A JP 2009549102A JP 2009549102 A JP2009549102 A JP 2009549102A JP 2010518082 A5 JP2010518082 A5 JP 2010518082A5
Authority
JP
Japan
Prior art keywords
alkyl
substituted
aryl
alkoxy
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009549102A
Other languages
English (en)
Japanese (ja)
Other versions
JP5425642B2 (ja
JP2010518082A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/001631 external-priority patent/WO2008115319A2/en
Publication of JP2010518082A publication Critical patent/JP2010518082A/ja
Publication of JP2010518082A5 publication Critical patent/JP2010518082A5/ja
Application granted granted Critical
Publication of JP5425642B2 publication Critical patent/JP5425642B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

JP2009549102A 2007-02-07 2008-02-07 合成ｔｌｒアゴニストの結合体およびそのための使用 Expired - Fee Related JP5425642B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US88869907P 2007-02-07 2007-02-07
US60/888,699 2007-02-07
PCT/US2008/001631 WO2008115319A2 (en) 2007-02-07 2008-02-07 Conjugates of synthetic tlr agonists and uses therefor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013059721A Division JP2013127004A (ja) 2007-02-07 2013-03-22 合成ｔｌｒアゴニストの結合体およびそのための使用

Publications (3)

Publication Number Publication Date
JP2010518082A JP2010518082A (ja) 2010-05-27
JP2010518082A5 true JP2010518082A5 (cg-RX-API-DMAC7.html) 2011-03-31
JP5425642B2 JP5425642B2 (ja) 2014-02-26

Family

ID=39766655

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009549102A Expired - Fee Related JP5425642B2 (ja) 2007-02-07 2008-02-07 合成ｔｌｒアゴニストの結合体およびそのための使用
JP2013059721A Withdrawn JP2013127004A (ja) 2007-02-07 2013-03-22 合成ｔｌｒアゴニストの結合体およびそのための使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013059721A Withdrawn JP2013127004A (ja) 2007-02-07 2013-03-22 合成ｔｌｒアゴニストの結合体およびそのための使用

Country Status (18)

Country Link
US (3) US8357374B2 (cg-RX-API-DMAC7.html)
EP (2) EP2125007B9 (cg-RX-API-DMAC7.html)
JP (2) JP5425642B2 (cg-RX-API-DMAC7.html)
KR (1) KR20090109121A (cg-RX-API-DMAC7.html)
CN (1) CN101790380B (cg-RX-API-DMAC7.html)
AU (1) AU2008227128B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0807196A2 (cg-RX-API-DMAC7.html)
CA (1) CA2677733A1 (cg-RX-API-DMAC7.html)
DK (1) DK2510946T3 (cg-RX-API-DMAC7.html)
EA (1) EA019151B1 (cg-RX-API-DMAC7.html)
ES (2) ES2456964T3 (cg-RX-API-DMAC7.html)
HU (1) HUE025555T2 (cg-RX-API-DMAC7.html)
IL (1) IL200240A (cg-RX-API-DMAC7.html)
PL (2) PL2125007T3 (cg-RX-API-DMAC7.html)
PT (1) PT2510946E (cg-RX-API-DMAC7.html)
SI (1) SI2510946T1 (cg-RX-API-DMAC7.html)
WO (1) WO2008115319A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200906094B (cg-RX-API-DMAC7.html)

Families Citing this family (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101304748A (zh) 2005-08-22 2008-11-12 加利福尼亚大学董事会 Tlr激动剂
CA2653941C (en) 2006-05-31 2013-01-08 The Regents Of The University Of California Substituted amino purine derivatives and uses thereof
EA019151B1 (ru) 2007-02-07 2014-01-30 Дзе Регентс Оф Дзе Юниверсити Оф Калифорния Конъюгаты синтетических агонистов tlr и их применение
EP2211841A4 (en) * 2007-10-15 2013-03-13 Cooperative Res Ct For Asthma METHOD FOR PROPHYLAXIS AND AGENTS FOR USE THEREIN
JP2011511073A (ja) * 2008-02-07 2011-04-07 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｔｌｒ７活性化物質による膀胱の疾患の治療
WO2010088924A1 (en) 2009-02-06 2010-08-12 Telormedix Sa Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
EP2396328A2 (en) 2009-02-11 2011-12-21 The Regents of The University of California Toll-like receptor modulators and treatment of diseases
EP2435094A2 (en) 2009-05-27 2012-04-04 Selecta Biosciences, Inc. Targeted synthetic nanocarriers with ph sensitive release of immunomodulatory agents
SI2491035T1 (sl) 2009-10-22 2017-10-30 Gilead Sciences, Inc. Derivati purina ali deazapurina uporabni za zdravljenje (med drugimi) virusnih okužb
JP2013525431A (ja) * 2010-04-30 2013-06-20 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 合成ｔｌｒ７アゴニストのリン脂質結合体の使用
AU2011247359A1 (en) * 2010-04-30 2012-11-15 Telormedix Sa Methods for inducing an immune response
KR20130056249A (ko) * 2010-04-30 2013-05-29 텔로메딕스 에스에이 인지질 약물 유사체
US9050319B2 (en) 2010-04-30 2015-06-09 Telormedix, Sa Phospholipid drug analogs
CA2798323A1 (en) 2010-05-26 2011-12-01 Selecta Biosciences, Inc. Dose selection of adjuvanted synthetic nanocarriers
WO2012038058A1 (en) 2010-09-21 2012-03-29 Telormedix Sa Treatment of conditions by toll-like receptor modulators
CN103517990A (zh) 2010-10-07 2014-01-15 通用医疗公司 癌症生物标志物
EP2640190A4 (en) 2010-11-05 2016-05-11 Selecta Biosciences Inc MODIFIED NICOTINIC COMPOUNDS AND ASSOCIATED METHODS
TR201815062T4 (tr) 2011-04-08 2018-11-21 Janssen Sciences Ireland Uc Viral enfeksiyonların tedavisine yönelik pirimidin deriveleri.
WO2012167088A1 (en) 2011-06-03 2012-12-06 3M Innovative Properties Company Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom
AU2012261959B2 (en) 2011-06-03 2015-12-03 Solventum Intellectual Properties Company Hydrazino 1H-imidazoquinolin-4-amines and conjugates made therefrom
MX2014001142A (es) 2011-07-29 2014-02-27 Selecta Biosciences Inc Nanoportadores sinteticos que generan respuestas inmunitarias humorales y de linfocitos t citotoxicos (ctl).
KR102025276B1 (ko) 2011-11-09 2019-09-25 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 바이러스 감염 치료를 위한 퓨린 유도체
EP3563872A1 (en) 2012-04-05 2019-11-06 Massachusetts Institute Of Technology Immunostimulatory compositions and methods of use thereof
PL2872515T3 (pl) 2012-07-13 2017-05-31 Janssen Sciences Ireland Uc Puryny makrocykliczne do leczenia infekcji wirusowych
CN103566377A (zh) * 2012-07-18 2014-02-12 上海博笛生物科技有限公司 癌症的靶向免疫治疗
WO2014052828A1 (en) 2012-09-27 2014-04-03 The Regents Of The University Of California Compositions and methods for modulating tlr4
MX386924B (es) 2012-10-10 2025-03-19 Janssen Sciences Ireland Uc Derivados pirrolo[3,2-d]pirimidínicos para el tratamiento de infecciones víricas y otras enfermedades.
CN105061567B (zh) * 2012-10-10 2021-07-20 深圳大学 免疫受体调节剂偶联体及其制备方法和应用、制备其的偶联前体以及合成偶联前体的化合物
EA035431B1 (ru) 2012-11-16 2020-06-15 Янссен Сайенсиз Айрлэнд Юси Гетероциклические замещенные производные 2-амино-хиназолина в качестве модуляторов tlr7 и/или tlr8 для лечения вирусных инфекций
SG11201506639XA (en) 2013-02-21 2015-09-29 Janssen Sciences Ireland Uc 2-aminopyrimidine derivatives for the treatment of viral infections
EP2958889B1 (en) * 2013-02-25 2017-03-22 The Scripps Research Institute Neoseptins: small molecule adjuvants
AU2014240165A1 (en) * 2013-03-14 2015-10-01 Rongfu Wang Methods and compositions for modulating regulatory T cell function
WO2014144365A1 (en) * 2013-03-15 2014-09-18 University Of Maryland, College Park Nano-liposomal formulations and methods of use
AU2014242954B2 (en) * 2013-03-29 2018-03-15 Janssen Sciences Ireland Uc Macrocyclic deaza-purinones for the treatment of viral infections
KR102280559B1 (ko) 2013-05-24 2021-07-22 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 바이러스 감염 및 추가적인 질환의 치료를 위한 피리돈 유도체
HRP20171720T1 (hr) 2013-06-27 2017-12-29 Janssen Sciences Ireland Uc Derivati pirolo [3,2-d] pirimidina za liječenje virusnih infekcija i drugih bolesti
CN105492446B (zh) 2013-07-30 2018-08-03 爱尔兰詹森科学公司 用于治疗病毒性感染的噻吩并[3,2-d]嘧啶衍生物
WO2015023858A2 (en) * 2013-08-16 2015-02-19 The Regents Of The University Of California Uses of phospholipid conjugates of synthetic tlr7 agonists
GB201321242D0 (en) 2013-12-02 2014-01-15 Immune Targeting Systems Its Ltd Immunogenic compound
GB201321737D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
SG11201605296SA (en) 2014-01-10 2016-07-28 Birdie Biopharmaceuticals Inc Compounds and compositions for treating her2 positive tumors
EP3760208B1 (en) 2014-06-25 2024-05-29 The General Hospital Corporation Targeting human satellite ii (hsatii)
DK3166976T3 (da) 2014-07-09 2022-04-11 Birdie Biopharmaceuticals Inc Anti-pd-l1-kombinationer til behandling af tumorer
WO2016022700A2 (en) 2014-08-06 2016-02-11 The Scripps Research Institute Tlr-independent small molecule adjuvants
EA032824B1 (ru) * 2014-08-15 2019-07-31 Чиа Тай Тяньцин Фармасьютикал Груп Ко., Лтд. Пирролопиримидиновые соединения, используемые в качестве агониста tlr7
CN112587672A (zh) 2014-09-01 2021-04-02 博笛生物科技有限公司 用于治疗肿瘤的抗-pd-l1结合物
US10034901B2 (en) 2015-01-22 2018-07-31 University Of Massachusetts Cancer immunotherapy
MX375989B (es) * 2015-05-26 2025-03-07 Ohio State Innovation Foundation Estrategia de vacuna basada en nanoparticulas contra el virus de la influenza porcina.
US20180161429A1 (en) 2015-06-26 2018-06-14 Beth Israel Deaconess Medical Center Inc. Cancer therapy targeting tetraspanin 33 (tspan33) in myeloid derived suppressor cells
DK3355933T3 (da) * 2015-09-29 2020-07-20 Sumitomo Dainippon Pharma Co Ltd Adeninkonjugatforbindelser og deres anvendelse som vaccineadjuvanser
CN105311032B (zh) * 2015-11-09 2018-09-25 深圳大学 Tlr7激动剂与酪氨酸激酶抑制剂联用在制备抗肿瘤药物中的应用
CN105315281B (zh) * 2015-11-16 2017-04-19 深圳大学 化合物i和化合物ii及其制备方法和应用
CN106943597A (zh) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 用于治疗肿瘤的抗-egfr组合
CN106943596A (zh) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 用于治疗肿瘤的抗-cd20组合
CN106943598A (zh) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 用于治疗肿瘤的抗-her2组合
EP3458028A1 (en) * 2016-05-16 2019-03-27 Infectious Disease Research Institute Pegylated liposomes and methods of use
US11697851B2 (en) 2016-05-24 2023-07-11 The Regents Of The University Of California Early ovarian cancer detection diagnostic test based on mRNA isoforms
CN109476675B (zh) 2016-07-01 2022-12-09 爱尔兰詹森科学公司 用于治疗病毒性感染的二氢吡喃并嘧啶衍生物
WO2018013924A1 (en) 2016-07-15 2018-01-18 Massachusetts Institute Of Technology Synthetic nanoparticles for delivery of immunomodulatory compounds
EP3519406B1 (en) 2016-09-29 2022-02-23 Janssen Sciences Ireland Unlimited Company Pyrimidine prodrugs for the treatment of viral infections and further diseases
WO2018077385A1 (en) * 2016-10-25 2018-05-03 Biontech Rna Pharmaceuticals Gmbh Dose determination for immunotherapeutic agents
CA3037046A1 (en) 2016-10-31 2018-05-03 University Of Massachusetts Targeting microrna-101-3p in cancer therapy
US11471515B2 (en) 2016-11-09 2022-10-18 The Brigham And Women's Hospital, Inc. Restoration of tumor suppression using MRNA-based delivery system
CN110087530A (zh) 2016-12-07 2019-08-02 普罗根尼蒂公司 胃肠道检测方法、装置和系统
US11426566B2 (en) 2016-12-14 2022-08-30 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with a TLR modulator
US11986480B2 (en) 2017-02-03 2024-05-21 Tohoku University Heterocyclic compound
CN118515666A (zh) 2017-04-27 2024-08-20 博笛生物科技有限公司 2-氨基-喹啉衍生物
US11517567B2 (en) 2017-06-23 2022-12-06 Birdie Biopharmaceuticals, Inc. Pharmaceutical compositions
US20200163880A1 (en) 2017-07-13 2020-05-28 Danmarks Tekniske Universitet Cationic liposomes
US10508115B2 (en) 2017-08-16 2019-12-17 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor
US10472361B2 (en) 2017-08-16 2019-11-12 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a benzotriazole moiety, conjugates thereof, and methods and uses therefor
US10457681B2 (en) 2017-08-16 2019-10-29 Bristol_Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor
US10487084B2 (en) 2017-08-16 2019-11-26 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor
US10494370B2 (en) 2017-08-16 2019-12-03 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor
US11814623B2 (en) 2018-01-30 2023-11-14 University Of Massachusetts Methods of treating a wound using epigenetic regulation
CA3090652A1 (en) 2018-02-06 2019-08-15 The General Hospital Corporation Repeat rna as biomarkers of tumor immune response
TW201945003A (zh) 2018-03-01 2019-12-01 愛爾蘭商健生科學愛爾蘭無限公司 ２，４－二胺基喹唑啉衍生物及其醫學用途
CN110317202B (zh) * 2018-03-30 2021-12-24 江苏恒瑞医药股份有限公司 氰基吡咯并杂芳基类衍生物、其制备方法及其在医药上的应用
CN108379591B (zh) 2018-04-03 2022-03-29 深圳大学 免疫激动剂靶向化合物的合成及其应用
WO2019196918A1 (zh) * 2018-04-13 2019-10-17 罗欣药业(上海)有限公司 五元杂环并嘧啶类化合物、药物组合物及用途
WO2019197598A1 (en) * 2018-04-13 2019-10-17 Glaxosmithkline Biologicals Sa Tlr7 and / or tlr8 agonists
US11485741B2 (en) 2018-04-24 2022-11-01 Bristol-Myers Squibb Company Macrocyclic toll-like receptor 7 (TLR7) agonists
US11554120B2 (en) 2018-08-03 2023-01-17 Bristol-Myers Squibb Company 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor
BR112021010717A2 (pt) * 2018-12-17 2021-08-31 Eisai R&D Management Co., Ltd. Formulação que compreende lipossomas
AU2020217716A1 (en) 2019-02-04 2021-08-26 Lonza Sales Ag Membrane protein scaffolds for exosome engineering
WO2020186229A1 (en) * 2019-03-14 2020-09-17 The Regents Of The University Of California Tlr4-tlr7 ligand formulations as vaccine adjuvants
WO2020191305A2 (en) 2019-03-20 2020-09-24 Massachusetts Institute Of Technology Uses of amphiphiles in immune cell therapy and compositions therefor
EP4671268A2 (en) 2019-03-21 2025-12-31 Lonza Sales AG METHOD FOR PREPARING EXTRACELLULAR VESICLES
US12502427B2 (en) 2019-03-21 2025-12-23 Lonza Sales Ag Extracellular vesicles for vaccine delivery
AU2020241903A1 (en) 2019-03-21 2021-10-14 Lonza Sales Ag Extracellular vesicle conjugates and uses thereof
US20230181758A1 (en) 2019-07-03 2023-06-15 Codiak Biosciences, Inc. Extracellular vesicles targeting dendritic cells and uses thereof
EP3994158A1 (en) 2019-07-03 2022-05-11 Codiak BioSciences, Inc. Extracellular vesicles targeting t cells and uses thereof
CA3150972A1 (en) * 2019-09-19 2021-03-25 Danmarks Tekniske Universitet Immune stimulating micelle composition
JP2022549328A (ja) 2019-09-25 2022-11-24 コディアック バイオサイエンシーズ， インコーポレイテッド 細胞外小胞組成物
EP4076445A1 (en) 2019-12-20 2022-10-26 Nammi Therapeutics, Inc. Formulated and/or co-formulated liposome compositions containing toll-like receptor ("tlr") agonist prodrugs useful in the treatment of cancer and methods thereof
EP4097103A1 (en) 2020-01-27 2022-12-07 Bristol-Myers Squibb Company 1h-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (tlr7) agonists
CN115135655B (zh) 2020-01-27 2024-07-02 百时美施贵宝公司 作为Toll样受体7(TLR7)激动剂的1H-吡唑并[4,3-d]嘧啶化合物
WO2021154663A1 (en) 2020-01-27 2021-08-05 Bristol-Myers Squibb Company 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
WO2021154666A1 (en) 2020-01-27 2021-08-05 Bristol-Myers Squibb Company 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
WO2021154668A1 (en) 2020-01-27 2021-08-05 Bristol-Myers Squibb Company 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
WO2021154664A1 (en) 2020-01-27 2021-08-05 Bristol-Myers Squibb Company 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
EP4097102A1 (en) 2020-01-27 2022-12-07 Bristol-Myers Squibb Company 1h-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (tlr7) agonists
KR20220132602A (ko) 2020-01-27 2022-09-30 브리스톨-마이어스 스큅 컴퍼니 톨-유사 수용체 7 (TLR7) 효능제로서의 1H-피라졸로[4,3-d]피리미딘 화합물
CN115151546A (zh) 2020-01-27 2022-10-04 百时美施贵宝公司 作为Toll样受体7(TLR7)激动剂的C3-取代的1H-吡唑并[4,3-d]嘧啶化合物
JP7735291B2 (ja) 2020-02-21 2025-09-08 エーアールエス ファーマシューティカルズ、インコーポレイテッド ネクチン－４抗体コンジュゲートおよびその使用
WO2021174024A1 (en) 2020-02-28 2021-09-02 First Wave Bio, Inc. Methods of treating iatrogenic autoimmune colitis
WO2021184017A1 (en) 2020-03-13 2021-09-16 Codiak Biosciences, Inc. Extracellular vesicles for treating neurological disorders
JP2023518414A (ja) 2020-03-20 2023-05-01 コディアック バイオサイエンシーズ， インコーポレイテッド 治療のための細胞外小胞
EP4149550A4 (en) * 2020-05-15 2024-07-03 The Board of Trustees of the Leland Stanford Junior University TOLL-LIKE RECEPTOR (TLR) AGONIST NANOPARTICLES AND USES THEREOF
WO2021237100A1 (en) 2020-05-21 2021-11-25 Codiak Biosciences, Inc. Methods of targeting extracellular vesicles to lung
WO2021248133A1 (en) 2020-06-05 2021-12-09 Codiak Biosciences, Inc. Anti-transferrin extracellular vesicles
CN111892648B (zh) * 2020-06-08 2022-08-26 中国科学院上海药物研究所 偶联tlr7激动剂的新型冠状病毒多肽疫苗及其应用
AU2021300362A1 (en) 2020-07-01 2023-02-23 ARS Pharmaceuticals, Inc. Anti-ASGR1 antibody conjugates and uses thereof
EP4175640A1 (en) 2020-07-02 2023-05-10 VIIV Healthcare Company Method of achieving hiv viral remission using long-acting antiretroviral agents
EP4216993A2 (en) 2020-09-23 2023-08-02 Codiak BioSciences, Inc. Methods of producing extracellular vesicles
WO2022066928A2 (en) 2020-09-23 2022-03-31 Codiak Biosciences, Inc. Process for preparing extracellular vesicles
WO2022066883A1 (en) 2020-09-23 2022-03-31 Codiak Biosciences, Inc. Extracellular vesicles comprising kras antigens and uses thereof
CA3196221A1 (en) * 2020-10-21 2022-04-28 Univerza V Ljubljani Conjugated tlr7 and nod2 agonists
WO2022200553A2 (en) 2021-03-25 2022-09-29 Danmarks Tekniske Universitet Immune stimulating nanoparticle composition
WO2022246764A1 (zh) * 2021-05-27 2022-12-01 中科蓝华(广州)生物医药技术有限公司 一种分析cd303+树突状细胞亚群表型和功能的方法及试剂盒
JP2024540425A (ja) * 2021-11-03 2024-10-31 アドセントルクス・セラピューティクス・インコーポレイテッド 薬物コンジュゲートならびにその調製方法および使用方法
CN116162088B (zh) * 2022-12-14 2025-03-11 江苏省农业科学院 一种Toll样受体7激动剂纳米颗粒及其制备方法与应用

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
CA1271477A (en) 1983-11-18 1990-07-10 John F. Gerster 1h-imidazo[4,5-c]quinolin-4-amines
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US5238944A (en) 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
US5736553A (en) 1988-12-15 1998-04-07 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo 4,5-C!quinolin-4-amine
US4929624A (en) 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
US5037986A (en) 1989-03-23 1991-08-06 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo[4,5-c]quinolin-4-amines
NZ232740A (en) 1989-04-20 1992-06-25 Riker Laboratories Inc Solution for parenteral administration comprising a 1h-imidazo(4,5-c) quinolin-4-amine derivative, an acid and a tonicity adjuster
ES2071340T3 (es) 1990-10-05 1995-06-16 Minnesota Mining & Mfg Procedimiento para la preparacion de imidazo(4,5-c)quinolin-4-aminas.
US5175296A (en) 1991-03-01 1992-12-29 Minnesota Mining And Manufacturing Company Imidazo[4,5-c]quinolin-4-amines and processes for their preparation
IL105325A (en) 1992-04-16 1996-11-14 Minnesota Mining & Mfg Immunogen/vaccine adjuvant composition
US5395937A (en) 1993-01-29 1995-03-07 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
US5648516A (en) 1994-07-20 1997-07-15 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
US5352784A (en) 1993-07-15 1994-10-04 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
US5525606A (en) 1994-08-01 1996-06-11 The United States Of America As Represented By The Department Of Health And Human Services Substituted 06-benzylguanines and 6(4)-benzyloxypyrimidines
DE19505168A1 (de) 1995-02-16 1996-08-22 Boehringer Mannheim Gmbh Spezifische Lipidkonjugate von Nucleosid-Diphosphonaten und deren Verwendung als Arzneimittel
US5624677A (en) 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
US5693811A (en) 1996-06-21 1997-12-02 Minnesota Mining And Manufacturing Company Process for preparing tetrahdroimidazoquinolinamines
US5741908A (en) 1996-06-21 1998-04-21 Minnesota Mining And Manufacturing Company Process for reparing imidazoquinolinamines
DE19637209B4 (de) 1996-09-12 2006-12-14 Siemens Ag Verfahren zum Steuern des Antriebsstrangs eines Kraftfahrzeugs und integrierte Antriebsstrangsteuerung
WO1998017279A1 (en) 1996-10-25 1998-04-30 Minnesota Mining And Manufacturing Company Immune response modifier compounds for treatment of th2 mediated and related diseases
DE122006000029I1 (de) 1996-10-25 2006-10-19 Gilead Sciences Inc Gefaesszellen Wachstumsfaktor (vegf) nukleins{ureligand-Komplexe
JPH10298181A (ja) 1997-04-25 1998-11-10 Sumitomo Pharmaceut Co Ltd タイプ２ヘルパーｔ細胞選択的免疫応答抑制剤
CA2309350C (en) 1997-11-12 2007-04-03 Mitsubishi Chemical Corporation Purine derivatives and medicaments comprising the same as active ingredient
AU732361B2 (en) * 1997-11-28 2001-04-26 Dainippon Sumitomo Pharma Co., Ltd. Novel heterocyclic compounds
JP4189048B2 (ja) 1997-12-26 2008-12-03 大日本住友製薬株式会社 複素環化合物
US7001609B1 (en) 1998-10-02 2006-02-21 Regents Of The University Of Minnesota Mucosal originated drug delivery systems and animal applications
US20020058674A1 (en) 1999-01-08 2002-05-16 Hedenstrom John C. Systems and methods for treating a mucosal surface
US6486168B1 (en) 1999-01-08 2002-11-26 3M Innovative Properties Company Formulations and methods for treatment of mucosal associated conditions with an immune response modifier
CA2361936C (en) 1999-01-08 2009-06-16 3M Innovative Properties Company Formulations comprising imiquimod or other immune response modifiers for treating mucosal conditions
CZ27399A3 (cs) 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
ATE345349T1 (de) 1999-12-17 2006-12-15 Ariad Pharma Inc Purinderivate
IL150060A0 (en) 1999-12-17 2002-12-01 Ariad Pharma Inc Novel purines
ATE322494T1 (de) 2000-01-07 2006-04-15 Universitaire Instelling Antwe Purin derivate, ihre herstellung und verwendung
US6733764B2 (en) 2000-06-14 2004-05-11 Alain Martin Immunostimulator anti-cancer compounds and methods for their use in the treatment of cancer
WO2002023186A2 (en) 2000-09-15 2002-03-21 Virco Bvba System and method for optimizing drug therapy for the treatment of diseases
GB0023008D0 (en) 2000-09-20 2000-11-01 Glaxo Group Ltd Improvements in vaccination
AU2002211602A1 (en) 2000-10-11 2002-04-22 Johns Hopkins University Polymer controlled delivery of a therapeutic agent
US20020127224A1 (en) 2001-03-02 2002-09-12 James Chen Use of photoluminescent nanoparticles for photodynamic therapy
DK1385823T3 (da) 2001-04-09 2007-03-26 Novartis Vaccines & Diagnostic Guanidinoforbindelser som melanocortin-4-receptor- (MC4-R) -agonister
US7157465B2 (en) 2001-04-17 2007-01-02 Dainippon Simitomo Pharma Co., Ltd. Adenine derivatives
AU2002316135B9 (en) 2001-05-18 2009-05-28 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
EP1401837B1 (en) 2001-06-29 2005-10-19 Cv Therapeutics, Inc. Purine derivatives as a2b adenosine receptor antagonists
AU2002343604C1 (en) 2001-10-30 2009-09-17 Conforma Therapeutics Corporation Purine analogs having HSP90-inhibiting activity
GB0206461D0 (en) 2002-03-19 2002-05-01 Glaxo Group Ltd Improvements in vaccination
CN1671412B (zh) 2002-08-15 2010-05-26 3M创新有限公司 免疫刺激组合物及刺激免疫反应的方法
AU2003271064B2 (en) 2002-09-27 2010-06-17 Dainippon Sumitomo Pharma Co., Ltd. Novel adenine compound and use thereof
JP2004137157A (ja) 2002-10-16 2004-05-13 Sumitomo Pharmaceut Co Ltd 新規アデニン誘導体を有効成分として含有する医薬
CN100387710C (zh) 2003-01-28 2008-05-14 上海三维生物技术有限公司 原发性癌和转移性癌相关的核酸
US20040265351A1 (en) 2003-04-10 2004-12-30 Miller Richard L. Methods and compositions for enhancing immune response
US20050004144A1 (en) 2003-04-14 2005-01-06 Regents Of The University Of California Combined use of IMPDH inhibitors with toll-like receptor agonists
US20050059613A1 (en) 2003-07-08 2005-03-17 Bahram Memarzadeh Compositions and methods for the enhanced uptake of therapeutic agents through the bladder epithelium
WO2005020892A2 (en) 2003-08-08 2005-03-10 Mitochroma Research, Inc. Pharmaceutical compositions and methods for metabolic modulation
OA13310A (en) 2003-09-05 2007-04-13 Anadys Pharmaceuticals Inc TLR7 ligands for the treatment of hepatitis C.
JP2005089334A (ja) 2003-09-12 2005-04-07 Sumitomo Pharmaceut Co Ltd ８−ヒドロキシアデニン化合物
BRPI0414533A (pt) 2003-09-18 2006-11-07 Conforma Therapeutics Corp composto, composição farmacêutica, e, métodos para inibir um hsp90 e para tratar um indivìduo tendo um distúrbio mediado por hsp90
FR2863890B1 (fr) * 2003-12-19 2006-03-24 Aventis Pasteur Composition immunostimulante
JP2007526322A (ja) 2004-03-02 2007-09-13 マサチューセッツ インスティテュート オブ テクノロジー ナノセル薬物送達系
MXPA06011080A (es) 2004-03-26 2007-04-16 Astrazeneca Ab Compuesto de 8-oxoadenina 9-sustituido.
EP1728792A4 (en) * 2004-03-26 2010-12-15 Dainippon Sumitomo Pharma Co 8-OXOADENINE COMPOUND
CA2587676A1 (en) 2004-11-19 2006-05-26 Institut Gustave Roussy Improved treatment of cancer by double-stranded rna
PT1819230E (pt) 2004-12-07 2012-08-07 Univ Miami Micropartículas derivadas de células vermelhas como agentes hemostáticos para o controlo da hemorragia e para o tratamento de patologias hemorrágicas
BRPI0609399A2 (pt) 2005-03-21 2010-03-30 Ferrer Int método para produzir compostos da 1h-imidazo[4,5-c]quinolin-4-amina 1-substituìda e intermediários dos mesmos
US20070292418A1 (en) 2005-04-26 2007-12-20 Eisai Co., Ltd. Compositions and methods for immunotherapy
CN101304748A (zh) 2005-08-22 2008-11-12 加利福尼亚大学董事会 Tlr激动剂
US20090118263A1 (en) 2005-09-22 2009-05-07 Dainippon Sumitomo Pharma Co., Ltd. Novel Adenine Compound
JPWO2007034917A1 (ja) 2005-09-22 2009-03-26 大日本住友製薬株式会社 新規なアデニン化合物
EA200800943A1 (ru) * 2005-09-27 2008-12-30 Коли Фармасьютикал Гмбх Модуляция tlr-опосредуемых иммунных ответов с использованием олигонуклеотидов-адаптеров
US20070100146A1 (en) 2005-11-03 2007-05-03 Trevor Dzwiniel Process for the preparation of imidazo[4,5-c]-quinolin-4-amines
CA2653941C (en) 2006-05-31 2013-01-08 The Regents Of The University Of California Substituted amino purine derivatives and uses thereof
US8338593B2 (en) 2006-07-07 2012-12-25 Gilead Sciences, Inc. Modulators of toll-like receptor 7
US7902187B2 (en) 2006-10-04 2011-03-08 Wyeth Llc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
WO2008043031A1 (en) 2006-10-04 2008-04-10 Pharmacopeia, Inc. 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
EA019151B1 (ru) 2007-02-07 2014-01-30 Дзе Регентс Оф Дзе Юниверсити Оф Калифорния Конъюгаты синтетических агонистов tlr и их применение
JP5395068B2 (ja) 2007-06-29 2014-01-22 ギリアード サイエンシーズ， インコーポレイテッド トール様受容体７の調節物質としてのプリン誘導体およびその使用
EP2200615A1 (en) 2007-10-16 2010-06-30 Gilead Palo Alto, Inc. A3 adenosine receptor antagonists
JP2011511073A (ja) 2008-02-07 2011-04-07 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｔｌｒ７活性化物質による膀胱の疾患の治療
WO2010088924A1 (en) 2009-02-06 2010-08-12 Telormedix Sa Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
EP2396328A2 (en) 2009-02-11 2011-12-21 The Regents of The University of California Toll-like receptor modulators and treatment of diseases
SI2491035T1 (sl) 2009-10-22 2017-10-30 Gilead Sciences, Inc. Derivati purina ali deazapurina uporabni za zdravljenje (med drugimi) virusnih okužb
JP2013525431A (ja) 2010-04-30 2013-06-20 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 合成ｔｌｒ７アゴニストのリン脂質結合体の使用
AU2011247359A1 (en) 2010-04-30 2012-11-15 Telormedix Sa Methods for inducing an immune response
KR20130056249A (ko) 2010-04-30 2013-05-29 텔로메딕스 에스에이 인지질 약물 유사체
BR112013005134A2 (pt) 2010-09-01 2018-04-24 Novartis Ag adsorção de imunopotenciadores em sais metálicos insolúveis
WO2012038058A1 (en) 2010-09-21 2012-03-29 Telormedix Sa Treatment of conditions by toll-like receptor modulators

Similar Documents

Publication Publication Date Title
JP2010518082A5 (cg-RX-API-DMAC7.html)
Yang et al. Reduction-responsive codelivery system based on a metal–organic framework for eliciting potent cellular immune response
US11938177B2 (en) Peptide vaccine formulations and use thereof for inducing an immune response
JP6993649B2 (ja) 免疫賦活活性を有するオリゴヌクレオチド含有複合体及びその用途
CN101790380B (zh) 合成tlr激动剂的缀合物及其应用
JP2021104038A (ja) 細胞透過性ペプチド、カーゴ、及びｔｌｒペプチドアゴニストを含む新規複合体
Nevagi et al. Self-assembly of trimethyl chitosan and poly (anionic amino acid)-peptide antigen conjugate to produce a potent self-adjuvanting nanovaccine delivery system
CN110743008A (zh) 基于纳米颗粒的组合物
EP3347047A1 (en) Expression vector delivery system and use thereof for inducing an immune response
CN104587464B (zh) 一种基于氢氧化铝纳米粒的疫苗载体
Xia et al. Functionalized multi-walled carbon nanotubes for targeting delivery of immunostimulatory CpG oligonucleotides against prostate cancer
CN115702005A (zh) 用于有效核酸递送的载体
CN112566672A (zh) 制造基于肽的疫苗的改进方法
JP2013510882A5 (cg-RX-API-DMAC7.html)
JP2025541816A (ja) Ｋｌｅｂｓｉｅｌｌａ ｐｎｅｕｍｏｎｉａｅに対するワクチン
WO2023148642A2 (en) Nanostructure-based vector system for bacterial and viral antigens
WO2024010971A1 (en) Lipid polysaccharide amino acid nanoparticles and use thereof
HK40049623A (en) Improved methods of manufacturing peptide-based vaccines
Nevagi Self-assembly of TMC and poly (anionic amino acid)-peptide antigen conjugate to produce a potent self-adjuvanting nanovaccine delivery system
Morris c12) United States Patent
HK1138767B (en) Conjugates of synthetic tlr agonists and uses therefor
HK1177886B (en) Conjugates of synthetic tlr agonists and uses therefor